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ABSTRACT
OBJECTIVE: The objective of this systematic EBM review is to determine “Does dupilumab
decrease the amount of asthma exacerbations in patients suffering from asthma compared to
placebo?”
STUDY DESIGN: A review of three randomized, placebo-controlled trials (RCTs) that were
peer reviewed and published in English after 2009.
DATA SOURCE: All articles were published in peer reviewed journals and were researched
using PubMed. Studies were selected based on their ability to answer the question posed in the
objective, and if the researched outcomes were patient oriented.
OUTCOMES: Assessed outcomes were either the occurrence or rate of asthma exacerbations
during the studies. The specifics of a defined exacerbation were similar, but minimally different
between each randomized controlled trial. Exacerbations according to the authors are as follows:
i.
Wenzel (2013): “>1 systemic glucocorticoid burst, in patient hospitalization, or an
emergency department visit for worsening asthma”
ii.
Wenzel (2016): “deterioration of asthma that required the use of systemic
corticosteroids for at least 3 days, or hospital admission or emergency department
visit because of asthma treated with systemic corticosteroids”
iii.
Rabe: “events leading to hospitalization, and ED visit, or treatment of >3days with
systemic glucocorticoids at >2 times the current”
RESULTS: All three studies found that Dupilumab had a large treatment effect on patients with
asthma and decreased exacerbations. Wenzel et al. (2013) found a NNT of three, with an odds
ratio (OR) of 0.08 (95% CI, 0.02 to 0.28, p<0.001) in favor of intervention decreasing risk for
exacerbation. Wenzel et al. (2016) had a NNT of seven, with a risk reduction percentage of
70.5% (95% CI, 45.4-84.1%, pvalue=0.0001) with Dupilumab intervention. And Rabe et al.
found an RR of 0.407 (95% CI, 0.263 to 0.630) meaning there is less than half the risk of an
exacerbation with intervention.
CONCLUSIONS: The results of these three studies showed that Dupilumab does decrease the
amount of asthma exacerbations compared to placebo in patients suffering from asthma.
However, further research with more patients needs to be conducted with more consistent
treatment protocols to understand optimal dosing.
KEYWORDS: Dupilumab, asthma

Campo – Dupilumab for Asthma Control 1
INTRODUCTION:
Asthma is a chronic disease with genetic predisposition that is characterized by varying
levels of airway obstruction, inflammation and hyperresponsiveness. Symptoms can be both
episodic or chronic, but are considered to be reversible either spontaneously or postbronchodilator therapy as reported by an increase of >12% in FEV1.1 The reversibility of
obstruction using a bronchodilator is what separates asthma from other obstructive lung diseases
such as chronic bronchitis or emphysema. Patients with persistent, moderate-severe asthma who
are uncontrolled may be having daily symptoms of wheezing, coughing and dyspnea despite
treatment with inhaled corticosteroids (ICS), long acting beta agonists (LABA) and rescue
inhalers putting them at a greater risk for exacerbations and hospital admission.1,2
Asthma is a common chronic disease amongst all age groups that effects healthcare
providers in many different settings. The incidence of asthma accounts for 24.6 million
Americans3, and more than 250 million people affected worldwide.2 Asthma patients account for
8-10% of the population1, and 20-25% of those diagnosed are considered to have moderate to
severe uncontrolled disease. Uncontrolled asthma, meaning that a patient still experiences
symptoms and exacerbations despite the use of maintenance medications such as ICS and some
other controller or systemic corticosteroids.2
With the increasing prevalence of asthma over the past 20 years, there is both a large
economic and resource burden placed on healthcare systems worldwide. In the United States
alone, there are some 10 million hospital visits and 1.8 million emergency room visits each year
as a result of asthma. These emergency room visits ultimately result in more than 3,500 deaths in
the US, most commonly amongst young blacks between the ages of 15 and 24.1 As a result, in
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2013 about $50.3 billion was spent in the US on medical costs for asthma alone, not including
the $29 billion from asthma-related mortality.4
Usual treatment methods depend largely on the severity and frequency of a patient’s
symptoms and are often approached with a stepwise treatment plan. This includes starting with a
short acting beta agonist such as albuterol for quick relief in addition to a maintenance ICS of
varying dosages such as budesonide or fluticasone for those with persistent asthma. LABAs such
as salmeterol are often added on for patients already on ICS with poor control, in addition to
other adjunct medications such as leukotriene receptor antagonists montelukast or zafirlukast.1
Biologic medications are being explored further as adjuncts for the treatment of uncontrolled
asthma. Omalizumab has been found to be helpful in patients with a positive skin test due to its
effect on the inhibition of IgE binding which has a key role in allergic asthma symptoms.1,2
Other biologics such as reslizumab and mepolizumab affect interleukin5, and have been found
effective in patients with elevated eosinophilic asthma. With poor asthma control, patients are
placed at a greater risk of a life-threatening exacerbation and a decreased quality of life.
Symptoms of breathlessness, inability to complete full sentences and a sensation of chest
tightness are common complaints during an asthma exacerbation. Exacerbations are treated with
a combination of supplemental oxygen, inhaled SABA via nebulizer or metered dose inhaler
(MDI) treatment, and oral systemic corticosteroids contributing to immunosuppression.
The mechanisms associated with poor asthma control in those who are using ICS and
LABAs is not fully understood.3 More recent research has come to find that about half of
patients with asthma have inflammatory cytokines attributed to type 2/Th2 inflammation, and
new therapies are being tested to reduce this specifically to improve control.2
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Dupilumab (Dupixent®) has shown success and improvement with other type 2
inflammatory disease processes such as atopic dermatitis and chronic sinusitis, common
comorbidities of asthma.2 This information is making researchers hopeful that Dupilumab, a
fully human monoclonal antibody, will be helpful in asthma control therapy through the
inhibition of interleukins-4 and 13 involved in Th2 inflammatory pathways.2 Dupilumab may be
used as an add-on controller medication to decrease the amount of severe exacerbations
experienced by asthma patients, especially those with moderate to severe asthma. This paper
evaluates three randomized placebo-controlled trials comparing the efficacy and safety of antiinterleuken-4 receptor monoclonal antibody Dupilumab in the treatment of persistent asthma and
its prevention of asthma exacerbations.
OBJECTIVE:
The objective of this systematic EBM review is to determine “Does Dupilumab decrease
the amount of asthma exacerbations in patients suffering from asthma compared to placebo?”
METHODS:
Resources and scholarly literature were selected by the author of this paper based on their
ability to answer the question: Does Dupilumab decrease the amount of asthma exacerbations in
patients suffering from asthma compared to placebo? The articles were also selected because
they discuss a new intervention being proposed for better asthma control that includes a patient
oriented outcome (POEM), in this case decreased occurrence of an exacerbation. All articles
were published in peer-reviewed journals in English, with exclusion criteria including articles
that were published before 2009. All three of the studies included are double-blind, randomized,
placebo-controlled clinical trials published in years 2013, 2016 and 2018 found using the key
words “Dupilumab” and “asthma” through the resource database Pubmed. Inclusion criteria
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Table 1. Demographics and Characteristics of Included Studies
Study
Type
#
Age
Inclusion
Exclusion
Patients (yrs)
Criteria
Criteria
Wenzel Double 104
Adults Patients 18-65
Patients
2013
blind
18 to
y/o, w/
outside of
RCT
65
persistent
the age
years
moderaterange, and
of age
severe asthma,
those with
>300 blood
low
eosinophil
eosinophil
count, and
counts;
poorly
ACQ5 score
controlled with outside of
medium-high
1.5-3.0
dose ICS; >1
exacerbation
within 2 years.
Wenzel Double 471
Adults Adults >18 y/o Diagnosis of
2016
blind
>18
with a diagnosis COPD or
RCT
years
of asthma >12
other lung
old
months, with
disease, use
medium-high
of PO
dosed ICS plus steroids
a LABA; FEV1 within 28
of 40-80% and
days of
ACQ5 score
screening,
>1.5 at
current
screening; >1
smokers, or
exacerbation
those who
within 1 year.
quit within 6
months.
Rabe
Double 210
Patients Patients >12
Patients <12
2018
blind
>12
y/o, with
y/o, under
RCT
years
physician
30 kg, and
of age
diagnosed
those with
asthma x1yr,
other COPD
receiving
or lung
treatment w/
diseases;
regular PO
current
glucocorticoids, smokers, or
and high dose
those with
ICS w/ a second URI or ER
controller;
treatment
FEV1 before
within 4
bronchodilator
weeks of
use of <80%
visit 1

W/D Interventions
24

300mg SQ
Dupilumab
every week
vs. placebo
while
discontinuing
their LABA
at week 4,
and
decreasing
ICS dose
during weeks
6-9.

34

300mg SQ
dupilumab q
2 or 4 weeks
following the
600mg
loading dose
at week one
vs. placebo

7

300mg SQ
Dupilumab
post 600mg
loading dose
q 2 weeks vs.
matched
placebo.
During
weeks 4-20,
steroid doses
were
decreased
q4wks
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included studies that were randomized controlled trails, and those published within the past 10
years. Statistics reported and used include OR, RR, NNT and p-values.
The selected studies, as detailed above in Table 1, include a population of patients
diagnosed with asthma, who were given the intervention of 300mg Dupilumab, at either weekly
or every two week frequencies depending on the study. Changes to patients’ previous asthma
control medications throughout each study slightly varied. The patients that were given the
intervention were all compared to an experimental group who received a similar appearing
placebo and the measured outcome was the occurrence or rate of asthma exacerbations.
OUTCOMES:
Outcomes were measured by the occurrence of a severe exacerbation in both Wenzel
studies, and as a rate of severe asthma exacerbations in Rabe 2018 study. The definitions of an
exacerbation were similar, but minimally different between studies.
I.

Wenzel (2013): “>1 systemic glucocorticoid burst, in patient hospitalization, or an
emergency department visit for worsening asthma”.3

II.

Wenzel (2016): “deterioration of asthma that required the use of systemic
corticosteroids for at least 3 days, or hospital admission or emergency department
visit because of asthma treated with systemic corticosteroids”.2

III.

Rabe: “events leading to hospitalization, and ED visit, or treatment of >3days with
systemic glucocorticoids at >2 times the current”.5

RESULTS:
Wenzel et al. (2013) study was a randomized placebo-controlled trial that took place in
28 different sites throughout the US. Patients were required to have an elevated eosinophil count
(>300 cells/µL) in addition to diagnosis of moderate to severe asthma not properly controlled
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with medium to high dose ICS and a LABA inhaler before the start of the trial. All patients were
between the ages of 18 and 65, with uncontrolled symptoms. A ratio of 1:1 was used to
randomize via a “centralized system” to achieve randomization allocation concealment.3 Patients
in the intervention group were given 300mg Dupilumab or placebo every week. Unique to this
study, patients were required to taper their maintenance medications such that they discontinued
their LABA at week four, and then continued to taper their ICS so that they would discontinue
by weeks six through nine of the total 12-week intervention period. This particular study looked
at the occurrence of an asthma exacerbation during the 12-week intervention as their primary
outcome, and patients continued to receive the study drug all 12 weeks or until they had an
exacerbation. Of those receiving Dupilumab, 6% had an exacerbation compared to 44% in the
placebo group (Table 2).3 The study reports an OR far below one, at 0.08 (95% CI, 0.02 to 0.28;
p<0.001) with Dupilumab, indicating that the intervention decreased the risk for asthma
exacerbation in this study in patients that were given the intervention compared to placebo.3
Given dichotomous data from the researchers, a NNT of 3 was calculated indicating that for
every three moderate to severe persistent asthmatics treated with Dupilumab, one more asthma
exacerbation will be prevented compared to the placebo. A low NNT and an OR significantly
smaller than one with a narrow CI, indicates a large treatment effect that is statistically
significant based on the reported p-value. It is important to note that although more than 20% of
the placebo group discontinued the study, it was due to a “lack of efficacy”, considering that the
patients had to discontinue their LABA and ICS. This means that patients were possibly
receiving no medication for their asthma control if given the placebo at the time of their
exacerbation.3
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Table 2. Occurrence of Asthma Exacerbation in Wenzel et al. 2013 Study
Intervention
Occurrence of asthma exacerbation during 12 wk
intervention
Dupilumab (n=52)
3 (6%)
Placebo (n=52)
23 (44%)
Wenzel et al. 2016 is a randomized placebo-controlled clinical trial that took place in 174
sites across 16 different countries. Patients in this 2016 trial had similar inclusion criteria such as
being >18 years old, with an asthma diagnosis for >12 months and those uncontrolled on
medium to high-dose ICS and a LABA inhaler. The main difference in patient population in this
study was that patients were selected irrespective of their blood eosinophil counts, including
those with greater than and less than 300 cells/µL.2 Results were reported for both the overall
population, and in the different subgroups based on eosinophil count. Reference exclusion
criteria in Table 1. With a total of 769 patients, there were four different intervention groups with
150-157 patients each, and a placebo group with 158. Randomization was achieved via a
centralized allocation system. Different interventions included receiving Dupilumab
subcutaneous (SQ) 200mg every two or four weeks, and 300mg every two or four weeks.2 All
intervention groups received a loading dose double that of their normal dose for the first
injection. More than 89% of patients completed the study (689/769 total patients).2
For this review, results regarding the 300mg SQ injection every two weeks were utilized
for calculation purposes and conclusions in this report. Amongst patients who received this
intervention, a statistically significant risk reduction percentage of 70.5% (95% CI, 45.4-84.1%,
p value=0.0001) was found when compared to placebo. Of those receiving Dupilumab 300mg
every two weeks, 11% suffered from an exacerbation compared to 26% in the placebo
intervention.2 Because this information was reported as dichotomous data within the study, NNT
of 7 was calculated indicating another large treatment effect. For every seven adults with
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uncontrolled persistent asthma treated with Dupilumab 300mg every two weeks, one more
person will have an asthma exacerbation prevented compared to placebo.
Table 3. Calculations for NNT in Both Wenzel et al. Studies
Study
EER
CER
RRR
Wenzel 2013 0.94
0.56
0.67
Wenzel 2016 0.89
0.74
0.20

ARR
0.38
0.15

NNT
3
7

The final study, by Rabe et al., was a randomized, placebo-controlled international study
that included 210 patients. Inclusion criteria in this study was slightly different and included
patients >12 years old, with an asthma diagnosis > 12 months with oral glucocorticoid dependent
severe asthma who were receiving systemic steroids within the six months preceding the study in
addition to a high dose ICS and up to two other inhalers. Review Table 1 for exclusion criteria.
Researchers allowed a three to 10 week adjustment period for the patient’s oral glucocorticoids
before beginning the 24 week intervention. Patients were either given 300mg SQ Dupilumab
with an initial loading dose of 600mg every two weeks, or matched placebo. Oral steroid doses
were reduced and adjusted during weeks four through 20.5 Randomization to receive placebo or
intervention was achieved via a “voice web response technology.”5
The rate of a severe exacerbation was recorded by the researchers, but this could not be
converted to dichotomous data for a NNT calculation. The study did however find a relative risk
versus placebo of 0.407 (95% CI, 0.263 to 0.630) meaning that there is less than half the risk of
an exacerbation with 300mg Dupilumab every two weeks compared to placebo.5 There is no
reported p-value. Although the treatment effect is also large, the existence of a wider confidence
interval makes the data found less precise, meaning that results in other studies may show
dissimilar results. However, there is not large concern that the intervention would increase the
risk of these patients’ exacerbations given that the CI does not exceed one. Loss of subjects who
did not complete the entire intervention was less than 20%.
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Among all three studies, the most common adverse event included an injection site
reaction and erythema, with other common events such as upper respiratory tract infection or
headache. Treatment was tolerable for patients in all studies. Notable to mention, in the study
done by Wenzel et al. 2016, there were two patient deaths, although they were in the intervention
group with Dupilumab 300mg every four weeks, not every two weeks. According to the authors,
the deaths were unrelated to treatment as one patient passed from acute heart failure and the
other from metastatic gastric cancer with complications of pneumonia and cor pulmonale.2 No
deaths were recorded in either of the two other studies.
Table 4. Most Common Adverse Events in All Studies
Study
Injection site
reaction
Wenzel Dupilumab (n=52)
15 (29%)
2013
Placebo (n=52)
5 (10%)
Wenzel Dupilumab (n=156) 33 (21%)
2016
Placebo (n=158)
12 (8%)
Rabe
Dupilumab (n=103) 9 (9%)
2018
Placebo (n=107)
4 (4%)

Upper resp.
Infection
7 (13%)
9 (17%)
20 (13%)
28 (18%)
9 (9%)
19 (18%)

Headache
6 (12%)
3 (6%)
17 (11%)
20 (13%)
Not reported
Not reported

DISCUSSION:
Previous clinical trials researching antibody treatment options for Th2 inflammatory
diseases have shown consistent positive results in patients with elevated eosinophil counts,
explaining why Wenzel et al. 2013 initially only included patients with blood eosinophil counts
>300 cells/µL.3 Interestingly enough, future studies including the other two analyzed in this
review have found that Dupilumab was successful in decreasing exacerbation risk and improving
lung function in asthma patients regardless of their baseline blood eosinophil count.2,5
There are other labeled uses for Dupilumab including moderate to severe atopic
dermatitis and chronic rhinosinusitis with nasal polyposis that were successful before using it in
trials as an adjunct asthma medication. Similar to when treating asthma, some of the most
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common adverse reactions found were injection site reactions.6 In studies specifically involving
patients with atopic dermatitis, severe eye irritation in addition to blepharitis, conjunctivitis and
keratitis were recorded as adverse effects not reported in asthma trials.7 The only
contraindication for Dupilumab found is a known hypersensitivity to the drug or any of its
components and there are currently no black box warnings.6,7 However, Dupilumab is known to
have drug interactions with live vaccines and simultaneous injections should thus be avoided if
possible. Patients who are using Dupilumab for atopic dermatitis are advised to continue taking
their asthma medications as directed unless otherwise advised by their healthcare provider to
prevent unnecessary exacerbations.6 Due to the successful treatment of several comorbid
conditions, it is possible that this one drug will be able to treat all conditions systemically at
once.2
Research on this topic was limited in the author’s search given that only PubMed was
used to find studies that answered the question: “Does Dupilumab decrease the amount of asthma
exacerbations in patients suffering from asthma compared to placebo?”. It is possible that there
are more, and better studies to be found on other databases. Limitations of the studies themselves
include relatively small sample size and short duration of treatment. In addition to that, the
methodology of each study was slightly different in how they altered their patients’ previous
medications making direct comparison more difficult. For example, in Wenzel et al. 2013 study,
patients were changing their maintenance medication at weeks four, six, and nine giving them
little time to adjust to each dose3. In the Rabe et al. study, the only medication that changed was
their oral corticosteroids, but these patients maintained their inhalers throughout the whole
study5. In addition to this, none of the studies included a “worst-case” analysis on patients lost to
follow-up. Both Wetzel et al. studies excluded missed data from their analysis, and Rabe et al.
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used a mixed model. It would increase validity to find risk reductions and a low NNT despite the
fact that all patients who left the study were counted towards exacerbation rates or counts in their
respective studies. A final limitation notable to mention found in the study by Rabe et al., is that
because the annualized rate of severe exacerbations reported was not the primary endpoint of
their study, it was not “controlled for comparison” and thus only reported a confidence interval,
but no p-value for complete statistical significance.5
CONCLUSION:
According to the results reported in this systemic review, Dupilumab does decrease the
amount of asthma exacerbations in patients diagnosed with asthma compared to placebo.
Statistically significant, large treatment effects were found in both studies published by Wetzel et
al. with small NNT of 3 and 7, and a significant risk reduction percentage with Dupilumab at
95% confidence in study by Rabe et al. Further research however needs to be done to confirm the
most ideal dose and administration schedule given that there were differences in that regard
amongst studies. Future research would be most beneficial if they included larger sample sizes,
and monitored treatment effects and adverse events for a longer period of time for increased
confidence in Dupilumab treatment of uncontrolled asthma. Data analysis could also be
incorporated to look at patients specifically with comorbid asthma and atopic dermatitis or
chronic sinusitis to monitor improvement of all conditions at the same time to see if there is
increased effect on one condition over another. And finally, patient population may also be
expanded to include children six and older, as use is approved in this age group for the treatment
of severe atopic dermatitis.6 Although other current ongoing studies with Dupilumab were not
found in my research, new treatment options for patients with uncontrolled asthma will continue
to benefit and one day improve the lives of millions affected by this common disease.
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